Agnieszka Witalisz-Siepracka
Overview
Explore the profile of Agnieszka Witalisz-Siepracka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Costanza M, Giordano C, von Brunneck A, Zhao J, Makky A, Vinh K, et al.
Br J Dermatol
. 2025 Mar;
PMID: 40036608
Background: Prognosis and quality of life of advanced cutaneous T cell lymphoma (CTCL) patients, in particular those with Sézary syndrome (SS) and advanced-stage mycosis fungoides (MF), are poor. Monoclonal antibodies...
2.
Karjalainen A, Witalisz-Siepracka A, Prchal-Murphy M, Martin D, Sternberg F, Krunic M, et al.
Cell Mol Life Sci
. 2025 Mar;
82(1):98.
PMID: 40025196
Tyrosine kinase 2 (TYK2) deficiency and loss or inhibition of kinase activity in men and mice leads to similar immune compromised phenotypes, predominantly through impairment of interferon (IFN) and interleukin...
3.
Weiss S, Zdarsky B, Witalisz-Siepracka A, Edtmayer S, Holzer A, Heindl K, et al.
Cancer Lett
. 2025 Jan;
613:217501.
PMID: 39864539
Acute myeloid leukemia (AML) is the most common acute leukemia and is predominantly affecting the elderly. It is a heterogenous disease, showing a broad spectrum of genomic alterations and mutations...
4.
Trifinopoulos J, List J, Klampfl T, Klein K, Prchal-Murphy M, Witalisz-Siepracka A, et al.
Haematologica
. 2024 Oct;
PMID: 39385738
Despite major therapeutic advances in the treatment of acute lymphoblastic leukemia (ALL), resistances and long-term toxicities still pose significant challenges. Cyclins and their associated cyclin-dependent kinases are one focus of...
5.
Witalisz-Siepracka A, Denk C, Zdarsky B, Hofmann L, Edtmayer S, Harm T, et al.
Front Immunol
. 2024 Jul;
15:1374068.
PMID: 39034990
Acute myeloid leukemia (AML) is a heterogenous disease characterized by the clonal expansion of myeloid progenitor cells. Despite recent advancements in the treatment of AML, relapse still remains a significant...
6.
Edtmayer S, Witalisz-Siepracka A, Zdarsky B, Heindl K, Weiss S, Eder T, et al.
Cell Death Dis
. 2024 May;
15(5):369.
PMID: 38806478
Signal transducer and activator of transcription 3 (STAT3) is frequently overexpressed in patients with acute myeloid leukemia (AML). STAT3 exists in two distinct alternatively spliced isoforms, the full-length isoform STAT3α...
7.
Klein K, Kollmann S, Hiesinger A, List J, Kendler J, Klampfl T, et al.
Blood
. 2024 Mar;
143(24):2474-2489.
PMID: 38498036
Patients with T- and natural killer (NK)-cell neoplasms frequently have somatic STAT5B gain-of-function mutations. The most frequent STAT5B mutation is STAT5BN642H, which is known to drive murine T-cell leukemia, although...
8.
Witalisz-Siepracka A, Klein K, Zdarsky B, Stoiber D
Front Immunol
. 2022 Jul;
13:947568.
PMID: 35865518
Signal transducer and activator of transcription 3 (STAT3) is a member of the Janus kinase (JAK)-STAT pathway, which is one of the key pathways contributing to cancer. STAT3 regulates transcription...
9.
Knab V, Gotthardt D, Klein K, Grausenburger R, Heller G, Menzl I, et al.
Cell Death Dis
. 2021 Oct;
12(11):991.
PMID: 34689158
Triple-negative breast cancer (TNBC) is an aggressive malignant disease that is responsible for approximately 15% of breast cancers. The standard of care relies on surgery and chemotherapy but the prognosis...
10.
Moser B, Edtmayer S, Witalisz-Siepracka A, Stoiber D
Biomedicines
. 2021 Aug;
9(8).
PMID: 34440253
Aberrant Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling is implicated in the pathogenesis of acute myeloid leukemia (AML), a highly heterogeneous hematopoietic malignancy. The management of AML is...